Price Chart

Profile

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
URL https://www.vrtx.com
Investor Relations URL https://investors.vrtx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release Feb. 07, 2024 (est.)
Last Earnings Release Nov. 06, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
URL https://www.vrtx.com
Investor Relations URL https://investors.vrtx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Growth
Next Earnings Release Feb. 07, 2024 (est.)
Last Earnings Release Nov. 06, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A